Compugen (NASDAQ:CGEN) Raised to Hold at ValuEngine
Separately, Zacks Investment Research raised shares of Compugen from a hold rating to a buy rating and set a $4.50 price target for the company in a research report on Wednesday.
Shares of Compugen stock traded down $0.09 during trading on Friday, hitting $3.90. 132,617 shares of the stock were exchanged, compared to its average volume of 92,306. The stock has a market cap of $204.66 million, a price-to-earnings ratio of -9.51 and a beta of 2.60. The firm’s 50-day moving average price is $4.10 and its 200 day moving average price is $3.68. Compugen has a 12-month low of $2.00 and a 12-month high of $4.50. The company has a debt-to-equity ratio of 0.11, a current ratio of 5.38 and a quick ratio of 5.38.
A number of institutional investors and hedge funds have recently made changes to their positions in CGEN. Nikko Asset Management Americas Inc. boosted its holdings in shares of Compugen by 84.0% during the second quarter. Nikko Asset Management Americas Inc. now owns 1,631,037 shares of the biotechnology company’s stock worth $6,263,000 after purchasing an additional 744,447 shares during the period. ARK Investment Management LLC increased its position in Compugen by 3.2% during the 2nd quarter. ARK Investment Management LLC now owns 8,496,641 shares of the biotechnology company’s stock valued at $32,627,000 after buying an additional 267,086 shares in the last quarter. ETF Managers Group LLC bought a new position in Compugen during the 2nd quarter valued at approximately $424,000. Renaissance Technologies LLC increased its position in Compugen by 20.7% during the 2nd quarter. Renaissance Technologies LLC now owns 557,800 shares of the biotechnology company’s stock valued at $2,142,000 after buying an additional 95,500 shares in the last quarter. Finally, Taylor Frigon Capital Management LLC increased its position in Compugen by 11.5% during the 2nd quarter. Taylor Frigon Capital Management LLC now owns 760,424 shares of the biotechnology company’s stock valued at $2,920,000 after buying an additional 78,278 shares in the last quarter. 29.95% of the stock is owned by hedge funds and other institutional investors.
Compugen Company Profile
Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel and Europe. The company's therapeutic pipeline consists of immuno-oncology programs against novel drug targets in the areas of unmet medical needs in various cancer types and patient populations.
Recommended Story: Municipal Bonds
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.com's FREE daily email newsletter.